PMV Pharmaceuticals (PMVP)
(Delayed Data from NSDQ)
$1.31 USD
+0.08 (6.50%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.30 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PMVP 1.31 +0.08(6.50%)
Will PMVP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PMVP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PMVP
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMVP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PMVP
Is PMVP building bullish momentum? Crossed Above 200 Day Moving Average shows up after surging 6.5%
200 Day Moving Average Resistance appears for PMVP after 1.6% move
Promising Phase 2 Trial Results and Strategic Plans Support Buy Rating for PMV Pharmaceuticals
PMVP forms Stochastic Buy Signal on September 17
Orbimed Advisors LLC Adjusts Holdings in PMV Pharmaceuticals Inc